FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to psychiatry and is applicable for laboratory diagnosing of schizotypal disorder. Substance of the invention consists in measuring blood serum glutamate in patients suffering endogenous psychoses. The mental patient is diagnosed with schizotypal disorder if measured blood serum glutamate is more than 20.12 nmol/ml.
EFFECT: using the presented invention provides more accurate diagnosis of schizotypal disorder, enables prescribing a well-timed and adequate treatment of the patient.
3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LABORATORY METHOD FOR DIAGNOSIS OF LEADING NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA | 2015 |
|
RU2578957C1 |
| LABORATORY DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR ENDOGENOUS PSYCHOSIS | 2013 |
|
RU2522236C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
| METHOD FOR PREDICTING INFRINGEMENTS IN COMPLIANCE WITH THERAPY FOR FURTHER CORRECTION OF PATIENTS WITH SCIZOPHRENIA | 2016 |
|
RU2611934C1 |
| METHOD FOR PREDICTION OF THE PROBABILITY OF AN UNFAVORABLE OUTCOME IN RELATION TO THE SOCIAL POSTPSYCHOTIC FUNCTIONING OF THE PATIENTS WITH ENDOGENOUS PSYCHIC DISEASES | 2018 |
|
RU2706216C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| LABORATORY DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR GUIDING POSITIVE AND NEGATIVE SEMIOLOGY IN SCHIZOPHRENIC PATIENTS | 2011 |
|
RU2482486C1 |
| LABORATORY METHOD OF DIAGNOSING BIPOLAR AFFECTIVE DISORDER | 2013 |
|
RU2558056C2 |
| METHOD OF PREDICTING COURSE OF NEUROTIC STRESS-ASSOCIATED DISORDERS | 2015 |
|
RU2613111C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
